E3 SUMO-protein ligase which facilitates SUMO1 and SUMO2 conjugation by UBE2I. Involved in transport factor (Ran-GTP, karyopherin)-mediated protein import via the F-G repeat-containing domain which acts as a docking site for substrates. Could also have isomerase or chaperone activity and may bind RNA or DNA. Component of the nuclear export pathway. Specific docking site for the nuclear export factor exportin-1.
Protein modification; protein sumoylation.
Defects in RANBP2 are the cause of susceptibility to encephalopathy acute necrotizing type 1 (ANE1) [MIM:608033]. A rapidly progressive encephalopathy manifesting in susceptibile individuals with seizures and coma. It can occur within days in otherwise healthy children after common viral infections such as influenza and parainfluenza, without evidence of viral infection of the brain or inflammatory cell infiltration. Brain T2-weighted magnetic resonance imaging reveals characteristic symmetric lesions present in the thalami, pons and brainstem.
All lanes : Anti-RanBP2 antibody (ab112061) at 0.04 µg/ml
Lane 1 : Hela whole cell lysate at 50 µg Lane 2 : Hela whole cell lysate at 15 µg Lane 3 : Hela whole cell lysate at 5 µg
Developed using the ECL technique.
Predicted band size: 358 kDa
Exposure time: 10 seconds
Immunoprecipitation - RanBP2 antibody (ab112061)
Detection of RanBP2 by Western Blot of Immunprecipitate.
ab112061 at 0.1µg/ml staining RanBP2 in HeLa whole cell lysate immunoprecipitated using ab112061 at 3µg/mg lysate (1 mg/IP; 20% of IP loaded/lane). Detection: Chemiluminescence with exposure time of 3 seconds.